Third Harmonic Bio Inc (THRD)

Currency in USD
5.38
0.00(0.00%)
Closed·
Unusual trading volume
Fair Value
Day's Range
5.355.43
52 wk Range
3.1816.02
Key Statistics
Prev. Close
5.38
Open
5.41
Day's Range
5.35-5.43
52 wk Range
3.18-16.02
Volume
1.42M
Average Volume (3m)
277.92K
1-Year Change
-54.17%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
THRD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.00
Downside
-44.24%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Third Harmonic Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Third Harmonic Bio Inc Company Profile

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Third Harmonic Bio Inc SWOT Analysis


Pioneering Therapy
Third Harmonic Bio's THB335, an oral wild-type KIT inhibitor, shows promise in treating mast-cell driven diseases, addressing an untapped area in inflammation and immunology
Market Potential
Analysts estimate peak US sales for chronic spontaneous urticaria at $2.7 billion, highlighting the significant commercial opportunity for THB335
Explore Clinical Progress
THB335's accelerated development timeline, with Phase 1 data expected in Q1 2025, positions Third Harmonic Bio for rapid advancement in the competitive biotech landscape
Financial Strength
With $255.3 million in cash and a current ratio of 42.5, Third Harmonic Bio is well-positioned to fund operations through 2026, supporting its ambitious clinical programs
Read full SWOT analysis

Compare THRD to Peers and Sector

Metrics to compare
THRD
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.2x
Upside (Analyst Target)
0.0%0.0%45.7%
Fair Value Upside
Unlock0.0%8.6%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 3.00
(-44.24% Downside)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-0.35 / -0.265
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

THRD Income Statement

FAQ

What Stock Exchange Does Third Harmonic Bio Trade On?

Third Harmonic Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Third Harmonic Bio?

The stock symbol for Third Harmonic Bio is "THRD."

What Is the Third Harmonic Bio Market Cap?

As of today, Third Harmonic Bio market cap is 242.79M.

What Is Third Harmonic Bio's Earnings Per Share (TTM)?

The Third Harmonic Bio EPS (TTM) is -1.25.

When Is the Next Third Harmonic Bio Earnings Date?

Third Harmonic Bio will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is THRD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Third Harmonic Bio Stock Split?

Third Harmonic Bio has split 0 times.

How Many Employees Does Third Harmonic Bio Have?

Third Harmonic Bio has 31 employees.

What is the current trading status of Third Harmonic Bio (THRD)?

As of 02 Aug 2025, Third Harmonic Bio (THRD) is trading at a price of 5.38, with a previous close of 5.38. The stock has fluctuated within a day range of 5.35 to 5.43, while its 52-week range spans from 3.18 to 16.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.